drugset
drugset / Trial / NCT00620503

Proellex® Pharmacokinetic Bridging Study II

NCT00620503 ↗

Phase 1 Completed 12 enrolled Repros Therapeutics Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

An open-label, randomized, single-center, outpatient, unblinded, single-dose, three-way crossover study of the safety and PK properties of Proellex® in women ages 18 - 34 years.

Timeline

Start
2008-02-29
Primary completion
2008-04-30
Completion
2008-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Telapristone Acetate Other / unclassified 25 mg —

Indications

No indication recorded.